In Israel, a small number of “heart muscle inflammations” were seen in people with the coronavirus vaccine developed by Pfizer/BioNTech, which is the world’s hopeful. The majority of the cases, which have not been conclusive, were 30 years old.
In Israel, which has had great success in vaccination against coronavirus, it has been reported that people with the vaccine developed by Pfizer/BioNTech have seen a small number of “heart muscle inflammation” (Myocarditis). The Israeli Health Ministry said in a statement that a small number of “heart muscle inflammation” (Myocarditis) occurred in people with the Pfizer/BioNTech vaccine, adding that cases had been investigated and no conclusions had been reached.
Most of the cases were seen among people aged 30
A preliminary study of more than 5 million vaccinated people identified “dozens of cases of myocarditis,” especially after the second dose, Israel’s Pandemic Response Coordinator Nachman Ash said in a statement. Ash said it was unclear whether this was unusually high and whether it was vaccine-related, adding that “the Department of Health is currently examining whether there is a surplus in the disease rate and whether it can be attributed to vaccines.” Ash described the issue as a “question mark”, stressing that the Ministry of Health has not yet concluded. Most of the cases were reported among people in their 30s.
Said it would be difficult to determine a link between the vaccine and myocarditis, explaining that myocarditis, a condition that usually disappears without complications, can be caused by various viruses and a similar number of cases have been reported in previous years. Pfizer/BioNTech said in a statement that the company is aware of myocarditis observations in a population of young men, mainly vaccinated against Pfizer/BioNTech Covid-19.
Pfizer/BioNTech said negative events are regularly and extensively reviewed. There was no causal connection to the vaccine. Currently, there is no evidence to conclude that myocarditis is a risk associated with the use of the Pfizer/BioNTech Covid-19 vaccine.”
Nadav Davidovitch, Director of the School of Public Health at Ben Gurion University in Israel, said in a statement that even if a correlation is established between myocarditis cases and the vaccine, it is not considered serious enough to stop the vaccine from being administered. “This is a situation that needs to be examined and we have to wait for the final report. However, in an interim analysis, the risk of getting sick from Covid-19 seems to be much higher than the risk of getting sick from the side effects of the vaccine. Myocarditis after vaccination is low and temporary.” While the Pfizer/BioNTech vaccine was administered to approximately 60 percent of Israel’s population of 9.3 million, the vaccine was found to be highly effective in preventing covid-19-related symptoms and serious diseases.